Biblio Discovery — Demo Discovery Service

11 hasil untuk "Annick Tibi"

Menampilkan 1–11 · 0,77 detik · RSS

  1. Artikel Jurnal Teks lengkap

    How to Improve the Implementation of Academic Clinical Pediatric Trials Involving Drug Therapy? A Qualitative Study of Multiple Stakeholders

    Delphine Girard; Olivier Bourdon; Hendy Abdoul dkk.

    PLoS ONE, Vol. 8 No. 5 · 2013 · Inggris · PLOS Scopus

    Objective: The need for encouraging pediatric drug research is widely recognized. However, hospital-based clinical trials of drug treatments are extremely time-consuming, and delays in trial implementation are common. The objective of this qualitative study was to collect information on the…

    Juga tersedia di: DOAJ

  2. Artikel Jurnal

    Academic pediatric clinical research: factors associated with study implementation duration

    Delphine Meier-Girard; Annick Tibi; Hendy Abdoul dkk.

    BMC Medical Research Methodology, Vol. 16 No. 1 · 2016 · Inggris · DOAJ Scopus

    Abstract Background The ethical, methodological, and technical aspects of pediatric research, often results in complications and delays in implementation. Our objective was to identify factors associated with the implementation duration of hospital-based pediatric studies. Methods All…

  3. Artikel Jurnal Teks lengkap

    Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial

    Xavier Duval; Sylvie van der Werf; Thierry Blanchon dkk.

    PLoS Medicine, Vol. 7 No. 11 · 2010 · Inggris · PLOS Scopus

    Analysis of virological and clinical outcomes from a randomized trial that was terminated early suggest that combined treatment of seasonal influenza in adult outpatients with oseltamivir plus zanamivir is no more effective than either oseltamivir or zanamivir monotherapy. Background: Neuraminidase…

    Juga tersedia di: DOAJ

  4. Artikel Jurnal Teks lengkap

    Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

    Olivier Hermine; Xavier Mariette; Pierre‐Louis Tharaux dkk.

    JAMA Internal Medicine · 2020 · Inggris · OpenAlex Scopus

    Importance: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). Objective: To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia. Design, Setting…

  5. Artikel Jurnal

    Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial

    Francis Berenbaum; Julien Champey; Jérémie Sellam dkk.

    BMJ Open, Vol. 12 No. 3 · 2022 · Inggris · DOAJ Scopus

    Introduction Patients with erosive hand osteoarthritis (EHOA) experience pain and inflammation, two features that can be targeted by vagus nerve stimulation using electrical auricular transcutaneous vagus nerve stimulation (tVNS). A pilot study demonstrated the feasibility of the procedure, so we…

  6. Artikel Jurnal

    Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

    Olivier Hermine; Xavier Mariette; Raphael Porcher dkk.

    EClinicalMedicine, Vol. 46 · 2022 · Inggris · DOAJ Scopus

    Summary: Background: In moderate-to-severe COVID-19 pneumonia, dexamethasone (DEX) and tocilizumab (TCZ) reduce the occurrence of death and ventilatory support. We investigated the efficacy and safety of DEX+TCZ in an open randomized clinical trial. Methods: From July 24, 2020, through May 18…

  7. Artikel Jurnal

    Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

    Ilias I. Siempos; Andre C. Kalil; Drifa Belhadi dkk.

    EClinicalMedicine, Vol. 69 · 2024 · Inggris · DOAJ Scopus

    Summary: Background: Although immunomodulators have established benefit against the new coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve outcomes without increasing the risk of secondary infections in the specific subgroup of previously immunocompromised…